ESMO Guidelines 2019
David Planchard, Institut Gustave Roussy, France
Progression after TKI’s: What’s next
Joop de Langen, AvL
Targeted treatment for oncogene addicted NSCLC
The time of ‘one size fits all’ lies behind us. Platinum-doublet chemotherapy as first line therapy for all patients with advanced non-small-cell lung cancer (NSCLC), followed by second line docetaxel upon progression for fit patients is a treatment of the past.
Major progress has been made in diagnostics (from none up to next generation sequencing and whole exome or genome sequencing) and therapeutic management, resulting in personalized therapy for every lung cancer patient.
As the diagnostic and therapeutic management of NSCLC evolves, the treating physician (you) has to evolve in the same pace. A modern pulmonary oncologist needs to be a molecular biologist, chemotherapist, immunologist, tyrosine kinase inhibitorist and palliative specialist, combined in one person.
During this presentation, we will discuss the diagnostic work-up of patients with advanced stage NSCLC, the interpretation of genetic results (is this mutation targetable or not), the therapeutic options for oncogene driven NSCLC, the use of liquid and tissue biopsies to identify TKI resistance and strategies to overcome TKI resistance.
Thymoma and SCLC treatment 2019
Giuseppe Giaccone, Lombardi Comprehensive Cancer Center, USA
Basics of IO treatment
Giorgio Scagliotti, Università di Torino, IT
The role of surgery in IO treatment
Joshua Sonett, NewYork-Presbyterian Hospital/Columbia University Medical Center, USA
The role of SBRT in IO treatment
Willemijn Theelen, AvL
The role of IO after concurrent chemo RT
Corey Langer, Abramson Cancer Center, USA
Machiel van der Woude Stipendium
Vera Bonta Award
Tafel discussie : Longkankerscreening in Nederland
Moderator: Frenk van der Linden Panelleden: Robin Cornelissen (Erasmus MC) Lidia Barberio (Longkanker Nederland) Joost Zaat (Wetenschaps journalist, NTVG) Lukas Stalpers (radiotherapeut, AUMC) Wanda de Kanter (Stichting Rookpreventie Jeugd), Harry de Koning (ErasmusMC)
Closing remarks and reception